ERBB2 and neoplasm: Across all analyzed tumor types, HER2 IHC scores were distributed as follows: 3.1% (n = 20) scored IHC3+, 13.2% (n = 86) scored IHC2+, and 19.8% (n = 129) scored IHC1+.